普利退: 关于公司股票及可转换公司债券终止上市暨摘牌的公告

Core Points - The company, Hainan Puli Pharmaceutical Co., Ltd., has had its stock and convertible bonds terminated from listing by the Shenzhen Stock Exchange due to false disclosures in its annual reports for 2021 and 2022, which amounted to a total of 669 million yuan, representing 73.83% of the total profits disclosed for those years [2][3] Group 1: Termination of Listing - The securities affected include common stock (stock code: 300630) and convertible bonds (bond code: 123099), with the termination decision effective from April 28, 2025 [2][3] - The company is required to ensure that its stock and convertible bonds can enter the delisting board for trading within 45 trading days after the termination [2] Group 2: Post-Termination Procedures - After the termination, the company has appointed Guotai Junan Securities Co., Ltd. as the lead broker for the trading of its stock and convertible bonds on the delisting board [4] - The company must handle the confirmation, registration, and custody of its securities in accordance with the regulations during the delisting process [4][5] Group 3: Investor Actions - Investors who submitted applications for conversion, redemption, or repurchase before the termination must resubmit their requests after the bonds are listed on the delisting board [1][5] - The company advises investors to complete the necessary procedures for the confirmation and registration of their securities to avoid delays in trading on the delisting board [5]